ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO846

The Difference of IgA1 O-Glycosylation Between IgA Nephropathy Transplant Recipients and IgA Deposition Donors

Session Information

  • Transplantation: Basic
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1801 Transplantation: Basic

Authors

  • Nakazawa, Shigeaki, Osaka University Graduate School of Medicine, Suita, Japan
  • Abe, Toyofumi, Oska University Graduate School of Medicine, Suita, Japan
  • Imamura, Ryoichi, Osaka University Graduate School of Medicine, Suita, Japan
  • Kato, Taigo, Osaka University, Suita, Japan
  • Nonomura, Norio, Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan
Background

IgA nephropathy (IgAN) is most common primary glomerulonephritis, and recurrence of IgAN after renal transplantation is frequent. On the other hand, IgA deposition (IgAD) from donor kidney without any manifestation of renal disease is often observed. The reason why IgA depositionD does not progress to IgA nephropathyN is not clear. In this study, we firstly analyzed the frequency of IgAD in living renal transplant donors, and we secondarily evaluated the IgA1 O-glycan structure in IgAN recipients, IgAD donors, and non-IgAD healthy donors (healthy donors).

Methods

We investigated O-glycan structure of IgA1 hinge region in 25 IgAN recipients, 17 IgAD donors, and 26 normal healthy donors matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Results

In O-glycans analysis using MALDI-TOF-MS, GalNAc and Gal content in HR of IgAN recipients were significantly decreased than IgAD donors and healthy donors. However, in all patterns of O-glycans, there was no significant difference between IgAD donors and healthy donors.

Conclusion

This is first report to compare the O-glycans structure in IgAN recipients and IgAD donors using MALDI-TOF-MS. Our result indicated that the decreased number of GalNAc and Gal content in HR could play pathogenic role in IgAN.

Funding

  • Government Support - Non-U.S.